STOCK TITAN

GRAIL to Present at the UBS Global Healthcare Conference

GRAIL (GRAL) management will present at the UBS Global Healthcare Conference on November 10, 2026, in Palm Beach, Florida.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

GRAIL (GRAL) management will present at the UBS Global Healthcare Conference on November 10, 2026, in Palm Beach, Florida. The presentation is scheduled for 11:00 a.m. ET. A live and replay webcast will be accessible at investors.grail.com, with the replay available for at least 30 days after the event.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, Nov. 10 at 11:00 a.m. ET. 

GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured.

A live and replay webcast may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the United Kingdom. 

For more information, visit grail.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-ubs-global-healthcare-conference-302921119.html

SOURCE GRAIL, Inc.

Keep reading